Veru Inc (NASDAQ:VERU) is set to release its Q2 2025 earnings on May 8, 2025. The consensus estimate for Q2 2025 revenue is $0.58 million, and the earnings are expected to come in at -$0.06 per share.

Veru Inc (NASDAQ:VERU) is set to release its Q3 2025 earnings on Aug 12, 2025. The consensus estimate for Q3 2025 revenue is $0.65 million, and the earnings are expected to come in at -$0.05 per share ...

Jan 27 (Reuters) - Veru (VERU.O), opens new tab said on Monday its experimental drug in combination with Novo Nordisk's (NOVOb.CO), opens new tab weight-loss treatment Wegovy, helped preserve muscle ...

The stock price of Veru Inc. (NASDAQ: VERU), a biopharmaceuticals company focused on oncology medicines, has seen a monstrous 112% rise over the last ten trading days, while it’s up 47% over the last ...

MIAMI, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), The Prostate Cancer Company, an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer ...

--VERU-111 has potential to treat both the SARS-CoV-2 virus infection and the severe inflammation leading to acute respiratory distress syndrome-- About Veru Inc.Veru Inc. is an oncology and urology ...

-- Combination Tablet Treats BPH Symptoms; Shrinks Prostate and Prevents BPH Progression -- -- NDA Submission Target Mid 2019 -- MIAMI, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an ...

March 14 (Reuters) - Drug developer Veru Inc (VERU.O), opens new tab on Tuesday said it plans to proceed with a late-stage trial of its COVID-19 pill, weeks after the U.S. health regulator declined to ...

In January 2020, Veru was coming off a quarter (the period ended Dec. 31, 2019) when it reported a net loss of $3.3 million on revenue of $10.6 million -- an impressive 66% improvement from the ...